In a notable development for the pharmaceutical industry, Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has received final approval from the United States Food and Drug Administration (USFDA) for the manufacture and market of Chlorpromazine Hydrochloride Injection USP. The approval encompasses two formulations: 25 mg/mL and 50 mg/2 mL (25 mg/mL) in Single-Dose […]
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer’s neurology drug candidate, PF-04958242, which is being developed to address cognitive impairment associated with schizophrenia (CIAS). The deal, potentially worth almost $600 million, includes an upfront payment of $75 million, with additional milestone payments and royalties that could total up to […]
